Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project

MD Anderson Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project (Deciphering Immunopathogenesis of MUCORmycosis to ADVANCE Risk Stratification, Diagnosis and Management of the Disease)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06878144

Enrollment

300

Registered

2025-03-14

Start date

2025-10-20

Completion date

2032-12-31

Last updated

2026-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mucormycosis

Brief summary

To collect data and samples from participants with cancer who also have invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection.

Detailed description

Primary Objective: To establish MD Anderson Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project. * To prospectively identify, collect, and store all isolates causing proven or probable MCM in adult high-risk cancer participants. * To prospectively identify, collect, and store relevant host samples from high-risk participants developing proven or probable MCM, along with relevant biospecimens from three control groups. * To comprehensively annotate clinical specimens and provide information regarding the course and outcome of all MCM cases and controls. OUTLINE: This is an observational study. Patients are assigned to 1 of 4 groups. GROUP M: Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study. GROUP A: Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study. GROUP B: Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study. GROUP C: Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study.

Interventions

BEHAVIORALMucormycosis

Tell the study team about any symptoms or side effects you have, follow study directions, and come to all study appointments (or contact the study team to reschedule).

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Patients must be 18-100 years old and have cancer and invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection but no evidence of such infection. * Patients must be willing to undergo routine diagnostic procedures (e.g., phlebotomy, bronchoscopy, biopsy) as part of their regular care.

Exclusion criteria

• Patients who are unwilling to undergo routine diagnostic procedures as part of their regular care.

Design outcomes

Primary

Measure	Time frame
Safety and Adverse Events (AEs)	Through study completion; an average of 1 year.

Countries

United States

Contacts

CONTACTDimitrios Kontoyiannis, MD

dkontoyi@mdanderson.org(713) 792-0826

PRINCIPAL_INVESTIGATORDimitrios Kontoyiannis, MD

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 15, 2026